Sandoz is betting on a decade-long boom in biosimilars to drive its next phase of growth, unveiling plans to more than double net sales by 2035 and build a portfolio of more than 100 biosimilars by 2040.

 

The Swiss affordable-medicines giant, which holds its Capital Markets Day for investors and analysts today, said its new Bio100 strategy will put biosimilars at the heart of its long-term expansion, with the company targeting a core EBITDA margin of more than 30% by 2035.

 

Sandoz currently has 13 biosimilars in its portfolio. Under Bio100, it aims to increase that figure to more than 100 by 2040 while expanding coverage of medicines facing loss of exclusivity (LoE) to around 80% from 2035 onwards, compared with about 50% today.

 

The company said it expects biosimilars to become the majority of its sales as it expands into more therapy areas and markets.

 

Richard Saynor, Chief Executive Officer, says: “Sandoz begins its next growth phase from a position of strength, built on a strong track record and a proven global platform. Our Bio100 ambitions are set to position biosimilars to become the majority of our sales, broadening access for patients while creating significant value for shareholders.

 

“The scale of our ambitions is matched by the strength of our plan: a leading biosimilar pipeline, a scalable, flexible and cost-competitive biosimilar development, manufacturing and supply network, best-in-class commercial engines, a culture to attract and retain the best talent and disciplined focus on value creation. This is our opportunity to accelerate our topline and further strengthen our leadership in biosimilars for years to come.”

 

Sandoz reaffirmed its existing mid-term outlook through 2028 while setting out a new 2025-2030 outlook.

 

The company is targeting mid-to-high single-digit compound annual growth in net sales at constant currencies over the period, alongside a core EBITDA margin of 25%-27% by 2030.

 

Longer term, Sandoz aims to more than double net sales from 2025 levels by 2035 through Bio100 and push its core EBITDA margin above 30%.

 

The company reported USD 11.1 billion in net sales in 2025, meaning the long-term target represents a substantial expansion of its business over the next decade.

 

Sandoz said the strategy is designed not only to increase sales, but also to broaden patient access to high-quality, affordable medicines worldwide.

 

The company sees biosimilars as a major growth opportunity as more high-value biologic medicines lose exclusivity.

 

Its Bio100 strategy is intended to give Sandoz greater scale across therapy areas and geographies while leveraging its development, manufacturing, supply and commercial infrastructure.

 

Sandoz said its growth plans are underpinned by a focus on profitability and value creation, alongside what it describes as a scalable and cost-competitive biosimilar platform.